Shanetta D Ore

Array ( [id] => 17149515 [patent_doc_number] => 11142578 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-12 [patent_title] => Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/814095 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 27 [patent_no_of_words] => 34052 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15814095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328289 [patent_doc_number] => 11633506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies [patent_app_type] => utility [patent_app_number] => 15/809427 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 71 [patent_figures_cnt] => 71 [patent_no_of_words] => 24522 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205859 [patent_doc_number] => 20180051085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'NOVEL ANTI-PD-1 CHECKPOINT INHIBITOR ANTIBODIES THAT BLOCK BINDING OF PD-L1 TO PD-1' [patent_app_type] => utility [patent_app_number] => 15/803193 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 23337 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12881050 [patent_doc_number] => 20180185525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS [patent_app_type] => utility [patent_app_number] => 15/792185 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15792185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479123 [patent_doc_number] => 20180291104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 15/721227 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15721227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158882 [patent_doc_number] => 20180030148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES' [patent_app_type] => utility [patent_app_number] => 15/715805 [patent_app_country] => US [patent_app_date] => 2017-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 77083 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15715805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051637 [patent_doc_number] => 11525008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Methods and pharmaceutical compositions for the treatment of lung cancer [patent_app_type] => utility [patent_app_number] => 16/335880 [patent_app_country] => US [patent_app_date] => 2017-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 7857 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12912619 [patent_doc_number] => 20180196049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => METHODS FOR DETECTION OF CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF CANCER IN A MAMMALIAN SUBJECT [patent_app_type] => utility [patent_app_number] => 15/710102 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15710102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12234256 [patent_doc_number] => 20180067120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'IDENTIFICATION AND ENRICHMENT OF CELL SUBPOPULATIONS' [patent_app_type] => utility [patent_app_number] => 15/698839 [patent_app_country] => US [patent_app_date] => 2017-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 48611 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15698839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12606735 [patent_doc_number] => 20180094075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => ANTI-PTK7 ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/693687 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15693687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219436 [patent_doc_number] => 20180057793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'METHODS FOR ISOLATING AND PROLIFERATING AUTOLOGOUS CANCER ANTIGEN-SPECIFIC CD8+ T CELLS' [patent_app_type] => utility [patent_app_number] => 15/691179 [patent_app_country] => US [patent_app_date] => 2017-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13596 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15691179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724390 [patent_doc_number] => 20180133297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 15/689159 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15689159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13806317 [patent_doc_number] => 10180422 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-01-15 [patent_title] => Methods of treating a neuroendocrine tumor [patent_app_type] => utility [patent_app_number] => 15/683630 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 9345 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15683630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435625 [patent_doc_number] => 20190175684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => MALIGNANT TUMOR TARGET PEPTIDE [patent_app_type] => utility [patent_app_number] => 16/326120 [patent_app_country] => US [patent_app_date] => 2017-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342913 [patent_doc_number] => 20180222996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => BISPECIFIC SCFV IMMUNOFUSION (BIF) [patent_app_type] => utility [patent_app_number] => 15/675493 [patent_app_country] => US [patent_app_date] => 2017-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15675493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184074 [patent_doc_number] => 20180043011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'PI3-Kinase Inhibition and LAG-3 Checkpoint blockade as a Combination Therapy for Cancer' [patent_app_type] => utility [patent_app_number] => 15/674066 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6464 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177370 [patent_doc_number] => 20180036306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND CD20 INHIBITORY ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/670743 [patent_app_country] => US [patent_app_date] => 2017-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 15401 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15670743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12127517 [patent_doc_number] => 20180011103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'CIRCULATING TUMOR CELL ASSAY' [patent_app_type] => utility [patent_app_number] => 15/661241 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 7816 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18354016 [patent_doc_number] => 11642400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Immunogenic/therapeutic glycan compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 15/662162 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 13871 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15662162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16260021 [patent_doc_number] => 10751430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Targeted radiotherapy chelates for in situ immune modulated cancer vaccination [patent_app_type] => utility [patent_app_number] => 15/658535 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 68 [patent_no_of_words] => 20882 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15658535 [rel_patent_id] =>[rel_patent_doc_number] =>)